Ibrutinib
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Trial Timeline
Apr 28, 2018 → May 31, 2019
NCT ID
NCT03476655About Ibrutinib
Ibrutinib is a pre-clinical stage product being developed by Johnson & Johnson for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03476655. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Lymphocytic, Chronic, B-Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03476655 | Pre-clinical | Completed |
| NCT03229200 | Approved | Active |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell